Navigation Links
FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
Date:2/1/2012

ata and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world.
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 The Institute for Healthcare Advancement ... award winners. The IHA Health Literacy Awards aim to ... on the practice of educating or empowering organizations to ... awards in three categories: innovative programs, published materials and ... Hero award. In the area of innovative ...
(Date:5/1/2015)... , May 1, 2015 Semler Scientific, Inc. ... company that develops, manufactures and markets products that assist ... today reported financial results for the first quarter ended ... quarter of 2015, Semler reported continued progress with year ... quarter revenue growth of 14%," said Doug Murphy-Chutorian ...
(Date:5/1/2015)... NEW YORK , May 1, 2015  Shares ... over 70% of their value yesterday following the results ... company,s glaucoma therapy, Rhopressa.  Despite the trial failing to ... indicates that positive results may come from future studies. ... a brief company overview, current pipeline, financial review, analyst ...
Breaking Medicine Technology:Institute for Healthcare Advancement Announces 2015 Award Winners 2Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... LAGUNA NIGUEL, Calif., Dec. 12, 2011  Inspiration Biopharmaceuticals, Inc. ... Company,s two lead hemophilia development programs - IB1001, a ... clinical trials for the treatment and prevention of ... an intravenous recombinant porcine factor VIII (FVIII) product, ...
... MALVERN, Pa., Dec. 11, 2011   TetraLogic Pharmaceuticals , ... drugs to treat cancer, today announced the oral presentation ... TL32711 at the 53rd ASH Annual Meeting and Exposition ... of Texas M. D. Anderson Cancer Center, demonstrated that ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH) 2Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH) 3Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH) 4Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH) 5TetraLogic Pharmaceuticals Announces Oral Presentation on Smac Mimetic TL32711 at American Society of Hematology (ASH) Annual Meeting 2
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 Vancouver fencing company, ... now provide valuable advice to prospective clients related to their ... looking to install railings around their decks and patios. While ... questions that pop up once the person rolls up their ... of installing a railing in finding a gate that matches ...
(Date:5/2/2015)... May 02, 2015 It’s a pattern ... natural disaster strikes anywhere on this planet, cyber scammers ... sympathy and compassion for their own personal gain. ... Emergency Readiness Team) issued an alert titled “Nepal ... email scams citing the earthquake in Nepal. The scam ...
(Date:5/2/2015)... On Tuesday April 7th, the patient ... to celebrate improvements in patient care. In 2014 the ... had zero acquired ventilator associated infections, zero central line ... was also recently named a Top Performer by the ... credited the teamwork of staff from all departments involved ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
Breaking Medicine News(10 mins):Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... LOS ANGELES, Dec. 11 At its 12th ... Group presented its Help Humanitarian Award to Steve,Mosko, ... his vibrant,humanitarian spirit and commitment to children with ... audience with his,performance of Conviction of the Heart. ...
... up-front preventive benefits add value to consumer-directed plan , ... Consumers are looking for ways to make the most of ... solution with Regence HSA Healthplan 2.0, which helps members manage ... Regence HSA Healthplan 2.0 pairs a high-deductible plan with a ...
... SAN ANTONIO - As cancer researchers move away from ... approaches, scientists are working to discover effective ways to ... San Antonio Breast Cancer Symposium illustrate the cutting edge ... Reductions in Breast Density Predict Potential Benefit of Tamoxifen ...
... Dec. 12 Alfacell Corporation (Nasdaq: ACEL ... financial officer and corporate secretary, will resign as an employee ... on the board of directors of Alfacell and will also ... until at least January 31, 2009. Mr. Kenyon has ...
... 12 Ogilvy Public Relations Worldwide (Ogilvy PR), ... has been awarded a five-year comprehensive communications support contract ... and Education. The work will be performed by Ogilvy ... the company,s life sciences consulting subsidiary, Feinstein Kean Healthcare ...
... Researchers not sure whether one causes the other, or ... 12 (HealthDay News) -- Adults who have panic disorder ... attacks and heart disease, but not heart-related deaths, a ... records of almost 58,000 adults diagnosed with panic disorder/attacks ...
Cached Medicine News:Health News:The Help Group's Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins 2Health News:Regence Unveils New Approach to Healthcare With Launch of HSA Healthplan 2.0 2Health News:Biomarkers: What can they tell us 2Health News:Alfacell Announces Management Update 2Health News:Alfacell Announces Management Update 3Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2Health News:Panic Disorder Linked to Higher Risk of Heart Disease 2
... From Medtronic, Inc., the leader in beating ... Positioner. The new Starfish NS device is ... to broaden patient acceptance of surgical revascularization.,The ... Perform the Multi-Vessel Small Thoracotomy (MVST) ...
... system is a key component ... CAB procedures. This expertly crafted ... mounting options. The unique rail ... blade configurations as well as ...
... Guidant's fourth generation access device - XPOSE ... the heart. The XPOSE 4 Device is ... off-pump bypass surgery and to easily position ... Designed for both apical and non-apical placement ...
... fit in tight spaces easily? Introducing ... - the latest innovation in mechanical ... equipped with low-profile feet, innovative FlexLink ... greater reach, maneuverability, and access to ...
Medicine Products: